Clinical Research on Alzheimer’s Disease: Progress and Perspectives

Multimodal Neuroimaging in Alzheimer’s Disease: Early Diagnosis, Physiopathological Mechanisms, and Impact of Lifestyle

(2018) Gaël Chételat   JOURNAL OF ALZHEIMERS DISEASE

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

(2018) Lawrence S. Honig et al.   NEW ENGLAND JOURNAL OF MEDICINE

Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study

(2018) Vijay R. Varma et al.   PLOS MEDICINE

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

(2017) Gordon K. Wilcock et al.   JOURNAL OF ALZHEIMERS DISEASE

Dementia prevention, intervention, and care

(2017) Gill Livingston et al.   LANCET

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

(2017) Petr Novak et al.   LANCET NEUROLOGY

Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers

(2017) Giovanni B Frisoni et al.   LANCET NEUROLOGY

Blood-derived amyloid-β protein induces Alzheimer’s disease pathologies

(2017) X-L Bu et al.   MOLECULAR PSYCHIATRY

Human umbilical cord plasma proteins revitalize hippocampal function in aged mice

(2017) Joseph M. Castellano et al.   NATURE

Tau-based therapies in neurodegeneration: opportunities and challenges

(2017) Chuanzhou Li et al.   NATURE REVIEWS DRUG DISCOVERY

A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain

(2017) Jun Wang et al.   Nature Reviews Neurology

Comorbidity Burden of Dementia: A Hospital-Based Retrospective Study from 2003 to 2012 in Seven Cities in China

(2017) Qing-Hua Wang et al.   Neuroscience Bulletin

Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts

(2017) Lih-Fen Lue et al.   Frontiers in Aging Neuroscience

Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score

(2017) Rahul S. Desikan et al.   PLOS MEDICINE

Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex

(2017) Jorge Sepulcre et al.   JAMA Neurology

Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden

(2017) Rachel F. Buckley et al.   JAMA Neurology

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

(2016) Eric R. Siemers et al.   Alzheimers & Dementia

The amyloid hypothesis of Alzheimer's disease at 25 years

(2016) Dennis J Selkoe et al.   EMBO Molecular Medicine

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Pharma pumps up anti-tau Alzheimer pipeline despite first Phase III failure

(2016) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS  -amyloid in animal models and in Alzheimers disease patients

(2016) M. E. Kennedy et al.   Science Translational Medicine

Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer’s Disease

(2016) Xiaoli Pan et al.   Neuroscience Bulletin

Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression

(2016) Henrik Zetterberg et al.   JAMA Neurology

Preclinical Assessment of Young Blood Plasma for Alzheimer Disease

(2016) Jinte Middeldorp et al.   JAMA Neurology

Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer’s disease

(2015) Yang Xiang et al.   ACTA NEUROPATHOLOGICA

Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models

(2015) Marc Aurel Busche et al.   NATURE NEUROSCIENCE

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice

(2014) Saul A Villeda et al.   NATURE MEDICINE

Developing novel blood-based biomarkers for Alzheimer's disease

(2013) Heather M. Snyder et al.   Alzheimers & Dementia

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

Plasma Amyloid-β as a Predictor of Dementia and Cognitive Decline

(2012) Alain Koyama et al.   ARCHIVES OF NEUROLOGY

An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A  Binding Properties Promotes Neuroprotection and Glial Engulfment of A 

(2012) O. Adolfsson et al.   JOURNAL OF NEUROSCIENCE

Immunotherapy for Alzheimer disease—the challenge of adverse effects

(2012) Yu-Hui Liu et al.   Nature Reviews Neurology

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Plasma tau protein in comatose patients after cardiac arrest treated with therapeutic hypothermia

(2011) E. MÖRTBERG et al.   ACTA ANAESTHESIOLOGICA SCANDINAVICA

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab

(2011) Susanne Ostrowitzki   ARCHIVES OF NEUROLOGY

SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study

(2010) Gareth Maher-Edwards et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization

(2009) R. C. Petersen et al.   NEUROLOGY